Abstracts Archive - Page 2242 of 2607 - ACR Meeting Abstracts

Abstract Number: 2896 • 2013 ACR/ARHP Annual Meeting
Damage In Systemic Lupus Erythematosus Is a Potentially Modifiable Outcome: Results From The Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Ian N. Bruce¹, Aidan O'Keefe², Li Su³, Vernon Farewell⁴, John G. Hanly⁵, Susan Manzi⁶, Murray B. Urowitz⁷ and Systemic Lupus International Collaborating Clinics (SLICC)⁸, ¹Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, ²MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom, ³MRC Biostatistics Unit, Cambridge, United Kingdom, ⁴MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom, ⁵Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, ⁶Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁷Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Systemic Lupus International Collaborating Clinics (SLICC), ON, Canada
Background/Purpose: Irreversible damage is an important outcome in patients with SLE. We aimed to study damage accrual in early SLE. We examined the rate of…
Abstract Number: 2897 • 2013 ACR/ARHP Annual Meeting
The Risk Of Deep Vein Thrombosis and Pulmonary Embolism In Systemic Lupus Erythematosus: A Population-Based Cohort Study
J. Antonio Avina-Zubieta¹, Eric C. Sayre², Diane Lacaille^1,3 and John M. Esdaile⁴, ¹Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: Previous hospital-based studies have shown that patients with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease, but limited population-based data are…
Abstract Number: 2858 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Chronic Pain By IL4-10 Synerkine Is Superior To IL-4 Or IL-10 Monotherapy: A Novel Strategy To Restrain Pain In Rheumatic Diseases
Niels Eijkelkamp¹, Sarita Hartgring², Cristine Steen-Louws³, Hanneke Willemen⁴, Qiu-Ling Mao-Ying⁵, Cobi Heijnen⁵, Erik Hack⁶, Annemiek Kavelaars⁵ and J.A.G. van Roon⁷, ¹Laboratory of Neuroimmunology and Developmental Origins of Disease (NIDOD), UMC Utrecht, Utrecht, Netherlands, ²Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³UMC Utrecht, Utrecht, Netherlands, ⁴NIDOD, UMC Utrecht, Utrecht, Netherlands, ⁵MD Anderson Cancer Center, Houston, TX, ⁶Immunology, UMC Utrecht, Utrecht, Netherlands, ⁷Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Chronic pain is a major problem in many diseases, including RA and OA, arising from inflammation or structural damage. It is often associated with glial…
Abstract Number: 2859 • 2013 ACR/ARHP Annual Meeting
Pain Pathway Activation In Dorsal Root Ganglia and Dorsal Horn In a Murine Surgical Model Of Osteoarthritis
Rachel E. Miller¹, Phuong Tran², Richard J. Miller³ and Anne-Marie Malfait⁴, ¹Rheumatology/Biochemistry, Rush University Medical Center, Chicago, IL, ²Rheumatology, Rush University Medical Center, Chicago, IL, ³Molecular Biochemistry and Pharmacology, Northwestern University, Chicago, IL, ⁴Internal Medicine/Biochemistry, Rush University Medical Center, Chicago, IL
Background/Purpose: Using a surgical mouse model of osteoarthritis (OA), destabilization of the medial meniscus (DMM), we monitor pain and associated pathways over a period of…
Abstract Number: 2860 • 2013 ACR/ARHP Annual Meeting
Mir-26a, Mir-30b and HER2: New Players On Lupus Nephritis Pathogenesis
Patrícia Costa-Reis¹, Pierre Russo² and Kathleen E. Sullivan³, ¹Allergy and Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Pathology, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: microRNAS (miRNAs) are noncoding RNAs responsible for post-transcriptional gene silencing. These key regulatory molecules control the expression of multiple genes, so its dysregulation can…
Abstract Number: 2861 • 2013 ACR/ARHP Annual Meeting
Accounting For Parental Load and Identification Of Multiple Risk Variants For Anti-Ro Congenital Heart Block Through High-Density Genotyping Of Immune-Related Loci
Robert M. Clancy¹, Jill P. Buyon², Nathalie Costedoat-Chalumeau³, Antonio Brucato⁴, Kateri Levesque⁵, Véronique Ramoni⁶, Miranda C. Marion⁷, Mary Comeau⁸, Satria Sajuthi⁹, Paula S. Ramos¹⁰, Robert P. Kimberly¹¹, Timothy D. Howard¹² and Carl D. Langefeld¹³, ¹Medicine, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Internal Medicine, Hopital Cochin, Paris, France, ⁴Internal Medicine, USC Internal Medicine, Ospedali Riuniti, Bergamo, Italy, ⁵Medicine Interne, Hopital Cochin, Paris, France, ⁶Rheumatology, Rheumatology University of Pavia, Pavia, Italy, ⁷Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, ⁸Wake Forest University Health Sciences, Winston-Salem, NC, ⁹Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ¹⁰Department of Medicine, Medical University of South Carolina, Charleston, SC, ¹¹Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹²Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC, ¹³Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC
Background/Purpose: Anti-Ro associated congenital heart block (CHB) exhibits a 33% concordance rate in monozygotic twins, 17.5% recurrence of disease and a high sibling risk ratio…
Abstract Number: 2862 • 2013 ACR/ARHP Annual Meeting
Autoantigen Microarray Analysis Of Sera From New-Onset Pediatric Systemic Lupus Erythematosus Patients: A Distinct Autoantibody Profile Associated With Class III/IV Lupus Nephritis
Imelda Balboni¹, David Haddon², Vivian Diep², Cindy Limb² and Paul Utz², ¹Pediatrics, Stanford University School of Medicine, Palo Alto, CA, ²Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous systemic autoimmune disease characterized by the production of autoantibodies directed against highly-conserved nuclear antigens. 15-20% of SLE…
Abstract Number: 2863 • 2013 ACR/ARHP Annual Meeting
Copy Number Variations Of Complement C4A and C4B Genes Are Genetic Risk Factor and Disease Modification Factor, Respectively, For Juvenile Dermatomyositis
Anjali Patwardhan¹, Katherine Lintner², Lisa G. Rider³, Frederick W. Miller³, Terrance O'Hanlon³, Yee Ling Wu⁴, Bi Zhou², Huanyu Wang⁴, David Newsom⁵, Peter White⁵, Charles H. Spencer⁶ and C. Yung Yu², ¹Pediatric Rheumatology, University of Missouri Women's and Children's Hospital, Columbia, MO, ²Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, ³Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁴The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, ⁵Biomedical Genomics Core, The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, ⁶Rheumatology, Nationwide Childrens Hospital, Columbus, OH
Background/Purpose: Juvenile Dermatomyositis (JDM) is a systemic and inflammatory vasculopathy that affects mainly proximal muscles and skin in children. It is a rare but severe…
Abstract Number: 2864 • 2013 ACR/ARHP Annual Meeting
Whole Exome Sequencing In Pediatric Patients With Early Onset Rare Immunodysregulatory Diseases That Present With Fever and Systemic Inflammation
Adriana Almeida de Jesus¹, Julie Niemela², Yin Liu³, Steven Boyden⁴, Ivona Aksentijevich⁵, Daniel L. Kastner⁶, Thomas A. Fleisher⁷, Raphaela Goldbach-Mansky³ and Zuoming Deng⁸, ¹Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ²Laboratory Medicine, NIH Clinical Center, Bethesda, MD, ³Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ⁴National Human Genome Research Institute, NIH, Bethesda, MD, ⁵Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁶Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD, ⁷Laboratory Medicine, Laboratory Medicine, NIH Clinical Center, Bethesda, MD, ⁸Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD
Background/Purpose: WES (Whole Exome Sequencing) has increasingly become the tool of choice in translational research, providing molecular diagnoses in Mendelian diseases and identifying important genes…
Abstract Number: 2865 • 2013 ACR/ARHP Annual Meeting
Gene Expression Profiles Of Fibroblast-Like Synoviocytes In Early Stage Of Oligoarticular Juvenile Idiopathic Arthritis Are Different In Extended Versus Persistent Course
AnneMarie C. Brescia¹, Megan M. Simonds², Suzanne M. McCahan², Paul T. Fawcett² and Carlos D. Rose¹, ¹Pediatric Rheumatology, Thomas Jefferson University/ AI duPont Hospital for Children, Wilmington, DE, ²Nemours Research, Nemours/AI duPont Hospital for Children, Wilmington, DE
Background/Purpose: Our goal is the identification of informative synovial biomarkers to predict persistent vs extended course in oligoarticular JIA patients. Methods: Stored remnant synovial fluid…
Abstract Number: 2866 • 2013 ACR/ARHP Annual Meeting
Determining The Absolute Change In The Clinical Disease Activity Index (CDAI) To Define a Minimally Important Difference
Jeffrey R. Curtis¹, Shuo Yang², Lang Chen³, Janet E. Pope⁴, Edward C. Keystone⁵, Boulos Haraoui⁶, Gilles Boire⁷, J. Carter Thorne⁸, Diane Tin⁹, Carol A. Hitchon¹⁰, Clifton O. Bingham III¹¹ and Vivian P. Bykerk¹², ¹University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴St Joseph Health Care, London, ON, Canada, ⁵Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁶Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁷Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ¹¹Rheumatology, Johns Hopkins University, Baltimore, MD, ¹²Divison of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Simplified measures to quantify rheumatoid arthritis (RA) disease activity are increasing in use in clinical practice. However, the absolute minimally important difference (MID) in…
Abstract Number: 2867 • 2013 ACR/ARHP Annual Meeting
Using Patient Reported Outcomes Measurement Information System Instruments To Identify Disease Flares In People With Rheumatoid Arthritis
Susan J. Bartlett^1,2, Ana-Maria Orbai³, Trisha Duncan³ and Clifton O. Bingham III³, ¹Clinical Epidemiology, McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ³Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Rheumatoid arthritis (RA) is associated with unpredictable episodes of disease worsening that may prompt consideration of treatment change. Core RA Flare domains have been…
Abstract Number: 2868 • 2013 ACR/ARHP Annual Meeting
Reliability and Validity Of Patient-Reported Joint Counts and Determinants Of Disagreement With The Physician In Recent Onset Rheumatoid Arthritis
Karen Visser¹, Janet E. Pope², Ernest Choy³, Clifton O. Bingham III⁴, Susan J. Bartlett^5,6, Gilles Boire⁷, Carol A. Hitchon⁸, J. Carter Thorne⁹, Boulos Haraoui¹⁰, Diane Tin¹¹, Edward Keystone¹² and Vivian P. Bykerk¹³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, St Joseph Health Centre, London, ON, Canada, ³Section of Rheumatology, Cardiff University, Cardiff, ENGLAND, United Kingdom, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD, ⁵Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁶Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ⁷Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, ¹³Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Patient-reported joint counts (JCs) might improve the efficiency and consistency of disease monitoring, self-management and early recognition of changes in disease activity in rheumatoid…
Abstract Number: 2869 • 2013 ACR/ARHP Annual Meeting
Changes In Patient-Reported Joint Counts and Composite Indices Can Identify Flare Of Disease Activity In Recent Onset Rheumatoid Arthritis
Karen Visser¹, Susan J. Bartlett^2,3, Clifton O. Bingham III⁴, Ernest Choy⁵, Daming Lin⁶, Juan Xiong⁷, Gilles Boire⁸, Boulos Haraoui⁹, Carol A. Hitchon¹⁰, Edward Keystone¹¹, Janet E. Pope¹², J. Carter Thorne¹³, Diane Tin¹⁴ and Vivian P. Bykerk¹⁵, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Clinical Epidemiology, McGill University, Montreal, QC, Canada, ³Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Division of Rheumatology, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Section of Rheumatology, Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, ⁶Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Mount Sinai Hospital, Toronto, ON, Canada, ⁸Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ¹⁰Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ¹¹Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, ¹²St Joseph Health Care, London, ON, Canada, ¹³Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁴The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁵Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Patient-reported joint counts (JCs) have been identified as core domains for assessment of flare in rheumatoid arthritis (RA).[1] To assess the responsiveness and discriminative…
Abstract Number: 2870 • 2013 ACR/ARHP Annual Meeting
Higher Disease Activity and Serum Levels Of Angiogenic Factors In Patients With Rheumatoid Arthritis In Clinical Remission With Synovitis On Ultrasound
Julio Ramirez¹, Virginia Ruiz-Esquide², Isaac Pomés³, Raquel Celis⁴, Jaume Pomés³, Sonia Cabrera¹, M. Victoria Hernández⁵, Oscar M Epis⁶, Jose L. Pablos⁷, Raimon Sanmarti¹ and Juan D. Cañete², ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clinic, Barcelona, Spain, ³Radiology, Hospital Clínic, Barcelona, Spain, ⁴Arthritis Unit, Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ⁵Arthritis Unit, Department of Rheumatology, Hospital Clinic, Barcelona, Barcelona, Spain, ⁶A.O. Ospedale Niguarda Cà Granda, Milan, Italy, ⁷Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain
Background/Purpose: To identify and characterize subclinical synovitis in patients with rheumatoid arthritis in clinical remission using power Doppler ultrasound and serum levels of angiogenic factors.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].